glp-1 stimulation and the kidney: from physiology to pharmacology and outcomes in diabetes Unlocking the multifaceted roles of

The Protein-Muscle Problem Research shows that up to 20 to 25 percent of weight lost on GLP-1 medications can come from muscle rather than fat

Leptin analogs and MC4R agonists are novel therapies that target genetic or hormonal causes of obesity

This popular weight loss can cause serious side effects and medical conditions.

GLP-1 agonists like semaglutide and tirzepatide are groundbreaking for weight loss

Instead of focusing on the mythology behind a slow metabolism or the oversimplification of "eat less to burn more," it is essential to acknowledge that metabolism is complex and flexible and is influenced by hormones, lifestyle habits, and revolutionary medical studies

Hands-on time: 1 Hr